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Background: The currently available antifungal drugs suffer from toxicity, greatest potential drug interactions with
other drugs, insufficient pharmacokinetics properties, and development of resistance. Thus, development of new
antifungal agents with optimum pharmacokinetics and less toxicity is urgent task. In the search for new azole
antifungals, we have been previously described azolylchromanone oxime ethers as rigid analogs of oxiconazole. In
continuation of our work, we incorporated phenylhydrazone moiety instead of oxime ether fragment in
azolylchromanone derivatives.
Methods: The 3-azolyl-4-chromanone phenylhydrazones were synthesized via ring closure of
2-azolyl-2'-hydroxyacetophenones and subsequent reaction with phenylhydrazine. The biological activity of title
compounds was evaluated against different pathogenic fungi including Candida albicans, Saccharomyces cerevisiae,
Aspergillus niger, and Microsporum gypseum. Docking study, in silico toxicity risks and drug-likeness predictions
were used to better define of title compounds as antifungal agents.
Results: The in vitro antifungal activity of compounds based on MIC values revealed that all compounds showed
good antifungal activity against C. albicans, S. cerevisiae and M. gypseum at concentrations less than 16 μg/mL.
Among the test compounds, 2-methyl-3-imidazolyl derivative 3b showed the highest values of drug-likeness and
drug-score.
Conclusion: The 3-azolyl-4-chromanone phenylhydrazones considered as analogs of 3-azolyl-4-chromanone oxime
ethers basically designed as antifungal agents. The antifungal activity of title compounds was comparable to that of
standard drug fluconazole. The drug-likeness data of synthesized compounds make them promising leads for future
development of antifungal agents.
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Recently, the incidence of life-threatening fungal dis-
eases has dramatically increased due to the rising num-
ber of immunocompromised patients, increased use of
anti-cancer drugs, and immunosuppressive therapy for
organ transplantation [1]. On the other hand, the cur-
rently available antifungal drugs suffer from toxicity,
greatest potential drug interactions with other drugs, in-
sufficient pharmacokinetics properties, and development* Correspondence: sd_emami@yahoo.com
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reproduction in any medium, provided the orof resistance [2]. Consequently, it is urgent to develop
new broad-spectrum antifungal agents with optimum
pharmacokinetics and less toxicity.
Several antifungal drugs, including azoles, polyenes,
echinocandins and allylamines have been developed to
overcome the fungal infections [3]. However, in com-
parison to the large number of antibacterial drugs the
number of clinically available antifungal agents is rather
low. Azole antifungals such as ketoconazole, fluconazole,
voriconazole, and posaconazole, which inhibit fungal
cytochrome P-450 dependent 14α-demethylase, are
among the most investigated compounds with respect to
their clinical impact and individual mechanism of actiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





Figure 2 Zinoconazole, a well-known azole antifungal bearing
phenylhydrazone substructure.
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heterocycles and act through a mechanism in which the
heterocyclic nitrogen atom (N-3 of imidazole or N-4 of
triazole) binds to the heme iron atom in cytochrome
P-450 enzymes. Particularly, the triazole derivatives have
a greater affinity for fungal cytochrome P-450 enzymes
than for mammalian ones contributing to a favorable
safety profile [5].
In the search for new azole antifungals, we have been
described azolylchromanone oxime ethers (Figure 1) as
rigid analogs of oxiconazole [6-8]. The chroman scaffold
also found in some natural flavonoids possessing antifun-
gal activity [9-11]. In continuation of our work, we incor-
porated phenylhydrazone moiety instead of oxime ether
fragment in azolylchromanone derivatives (Figure 1).
This modification was made on the basis of zinocona-
zole, a well-known azole antifungal possessing phenyl-
hydrazone substructure (Figure 2). Thus we describe
here, the synthesis and antifungal activity of 3-azolyl-4-
chromanone phenylhydrazones. Furthermore, docking
study and in silico toxicity risks and drug-likeness pre-




All chemical reagents and solvents were purchased from
Merck AG Chemical (Germany) and used without fur-
ther purification. The progress of reactions and the pur-
ity of compounds were checked by TLC analysis on
silica gel 60 F254 plates (Merck) and visualization was
done with UV light (254 nm). Melting points were deter-
mined in open glass capillaries using Bibby Stuart Scien-
tific SMP3 apparatus (Stuart Scientific, UK) and are
uncorrected. The IR spectra were recorded on FT-IR
(PerkinElmer, USA) spectrophotometer using KBr disks.
1 H-NMR spectra were recorded using a Bruker 400
(Rheinstatten, Germany) spectrometer, and chemical
shifts are expressed as δ (ppm) with tetramethylsilane as














Figure 1 Structures of azolylchromanone oxime ethers as rigid analo
chromanone phenylhydrazones.Finnigan MAT TSQ-70 spectrometer (Finnigan MAT,
Germany).
General procedure for the synthesis of 3-azolyl-4-
chromanone derivatives 2a-c
Compounds 2a-c was synthesized from 2-azolyl-2'-
hydroxyacetophenones 1a-c according to the literature
methods [6-8].
General procedure for the synthesis of phenyhydrazone
derivatives 3a-c
Phenylhydrazine hydrochloride was added to a solution
of compound 2 (0.5 mmol) in methanol (4 mL) and the
solution was stirred at room temperature. The comple-
tion of the reaction was checked by TLC. After con-
sumption of compound 2 (3–7 days), water was added
and the mixture was left in refrigerator overnight. The
precipitated solid was separated by filtration and washed




Yield 55 %; IR (KBr, cm-1) 3418, 3238, 3128, 1703,













X = CH, N
R1 = H, Cl



































































Scheme 1 Synthetic routes to phenylhydrazone derivatives
3a-c. (a) paraformaldehyde, AcOH, reflux; (b) phenylhyrazine
hydrochloride, MeOH, r.t.; (c) acetaldehyde, AcOH, 90°C.
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δ 4.44 (m, 1 H), 4.82-4.87 (m, 1 H), 5.99 (dd, 1 H, J=10.8
and 6.6 Hz), 6.79-6.90 (m, 2 H), 7.04 (t, 2 H, J=7.2 Hz),
7.12-7.26 (m, 3 H), 7.66 (dt, 1 H, J=7.4 and 2.0 Hz), 7.83
(dd, 1 H, J=7.6 and 2.0 Hz), 8.43 (s, 1 H), 8.64 (s, 1 H),
10.05 (s, 1H). Anal. Calcd for C17H15N5O: C, 66.87; H,
4.95; N, 22.94. Found: C, 66.98; H, 5.14; N, 22.71.
trans-2,3-Dihydro-3-(1H-imidazol-1-yl)-2-methyl-4H-1-
benzopyran-4-one phenylhydrazone (3b)
Yield 62%; m.p. 228–230°C; IR (KBr, cm-1) 3444, 3246,
1603, 1567, 1498, 1457, 1295, 1255, 1220, 1124, 834,
750, 696. 1H NMR (400 MHz, DMSO-d6) δ 1.16 (d,
3 H, J= 6.4 Hz), 5.19 (dq, 1 H, J= 12.4 and 6.4 Hz),
5.88 (d, 1 H, J= 12.8 Hz), 6.75 (d, 2 H, J= 7.2 Hz),
6.83 (t, 1 H, J= 8.0 Hz), 6.92 (t, 2 H, J= 8.0 Hz), 7.01
(d, 1 H, J= 8.0 Hz), 7.11 (t, 1 H, J= 7.6 Hz), 7.14-7.36
(m, 3 H), 7.68 (t, 1 H, J= 8.4 Hz), 8.07 (d, 1 H, J= 7.6 Hz),
10.34 (s, 1 H). Anal. Calcd for C19H18N4O: C, 71.68; H,
5.70; N, 17.60. Found: C, 71.50; H, 5.79; N, 17.86.
7-Chloro-2,3-dihydro-3-(1H-imidazol-1-yl)-4H-1-benzo-
pyran-4-one phenylhydrazone (3c)
Yield 58%; m.p. 192–194°C; IR (KBr, cm-1) 3444, 1602,
1560, 1497, 1418, 1252, 1163, 1082, 814, 754, 696. MS
(m/z, %) 338 (M+, 25), 270 (100), 207 (10), 154 (15), 105
(28), 77 (78), 67 (37). Anal. Calcd for C18H15ClN4O: C,
63.81; H, 4.46; N, 16.54. Found: C, 63.66; H, 4.28; N, 16.57.
Antifungal activity
The antifungal activities of title compounds 3a-c and 2b
were tested against several representative pathogenic
fungi including Candida albicans PTCC 5027 and Sac-
charomyces cerevisiae PTCC 5177 (as yeast), Micro-
sporum gypseum PTCC 5070 (as a dermatophyte) and
Aspergillus niger PTCC 5012 (as a mould) using agar di-
lution method [12]. Stock solutions of tested compounds
were prepared in DMSO and serially diluted. Sabouraud
Dextrose Agar was used for fungal growth. Inocula con-
taining approximately 105 CFUs/mL of fungi were pre-
pared from broth cultures in log phase growth. Fungal
plates were made in triplicate and incubated at 30°C
about 24–48 h for yeast, about 72 h for moulds and
about 168 h for dermatophytes. The MIC value was
defined as lowest concentration of the antifungal agent
at which the test strain does not demonstrate visible
growth. The reported MICs are representative of at least
two independent experiments.
Docking study
Crystal structure of cytochrome P450 14α-sterol
demethylase (Cyp51) from Mycobacterium tuberculosis
in complex with fluconazole (ID 1EA1) was provided
from the Protein Data Bank and prepared for docking
calculations using AutoDock Tools 1.5.4 with default
settings. Docking was performed using AutoDock vina,and standard parameters were used. Water molecules
were not included. The binding site was defined to any
residues with 10 Å distant from the co-crystallized fluco-
nazole in the complex crystal structure of the enzyme
[13].
In silico drug-likeness and toxicity predictions
OSIRIS Property Explorer [14] was used to estimate the
risks of side effects, such as mutagenic, tumorigenic, irri-
tant and reproductive effects, as well as drug-relevant
properties including cLogP, LogS (solubility), MW, drug-
likeness and overall drug-score.
Results and discussion
Chemistry
The synthetic route to phenylhydrazone derivatives 3a-c
was illustrated in Scheme 1. The starting 2-azolyl-2'-
hydroxyacetophenones 1a-c was prepared from corre-
sponding 2-bromo-2'-hydroxyacetophenones according
to the literature method [15]. Cyclization of compounds
1a-c with paraformaldehyde or acetaldehyde in refluxing
acetic acid gave 3-azolyl-4-chromanones 2a-c [6-8]. The
synthesis of hydrazone derivative 3a was first attempted
by reaction of 3-triazolyl-4-chromanone 2a with phenyl-
hydrazine hydrochloride in refluxing methanol in the
presence of Na2CO3 as a base, which resulted in poor
yield with mixture of unknown degraded products. Since
the condensation reactions of amines and hydrazines
with ketones are commonly catalyzed by acids or bases,
thus the alternative condition was using hydrochloride
salt of phenylhydrazine in the absence of a base. Accord-
ingly, the reaction of compound 2a-c with phenylhydra-
zine hydrochloride in methanol at room temperature
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seems that the acid released by hydrochloride salt of
phenylhydrazine is adequate for catalyzing the condensa-
tion reaction.
Theoretically, the reactivity of chromanone derivatives
toward N-nucleophiles like substituted hydrazine related
to two sites; carbonyl group and C-2 position (Scheme 2).
The attack of hydrazine to the C-2 position of chroman
ring could result in ring opening and subsequent pyrazo-
line formation.
Previously, the reaction of chromanone and flavanone
derivatives with substituted hydrazines has been in-
vestigated in different conditions [16,17]. Kállay et al.
have been reported that the flavanone hydrazones are
predominantly obtained under acidic conditions while
alkaline conditions give the pyrazolines and the 2-
hydroxychalcone derivatives due to the ring cleavage of
the hetero ring of chromanone [16]. Similarly, in our ex-
periment with 3-azolyl-4-chromanones, the hydrazone
derivatives were predominantly obtained under mild
acidic conditions, but in the presence of weak base
Na2CO3, possibly produced a mixture of corresponding
hydrazone, acyclic N-substituted hydrazine and pyrazo-
line derivatives which was difficult to separate and
characterize (Scheme 2).
The structures of compounds 3a-c were properly char-
acterized by IR, 1H NMR or Mass spectroscopy as well
as elemental analyses. For example, elemental analysis
proved the molecular formula of compound 3b as
C19H18N4O. The IR spectra of compound 3b did not
show any absorption due to the presence of C =O group
and a broad band was found in 3444 cm-1 due to the
presence of a N−H bond. The 1H NMR spectrum of 3b
showed a singlet at 10.34 for NH, a double at 8.07
(J= 7.6 Hz) and a triplet at 7.68 (J= 8.4 Hz) for H-5 and





























Scheme 2 Possible reactivity of 3-triazolylchroman-4-one
derivative 2a toward phenylhydrazine.imidazole protons was observed as a multiplet at the
range of 7.14-7.39 ppm. The H-6 and H-8 of chroman
ring resonated as a triplet at 7.11 and a doublet at
7.01 ppm. Five protons related to the phenyl group
appeared at 6.92, 6.83 and 6.75 ppm. The aliphatic pro-
tons of chroman (H-3 and H-2) resonated as a doublet
at 5.88 and a doublet of quartet at 5.19 ppm. A doublet
appeared at 1.16 ppm, assigned to the methyl protons.
Antifungal activity
The antifungal activities of title compounds 3a-c were
tested against several representative pathogenic fungi.
The resulting MICs (minimum inhibitory concentra-
tions) of hydrazone compounds were compared with
those of fluconazole as a reference antifungal agent and
intermediate compound 2b (Table 1). The results re-
vealed that 2-methyl-3-imidazolylchroman-4-one (2b)
showed no activity against Saccharomyces cerevisiae,
Aspergillus niger and Microsporum gypseum (MIC >64
μg/mL). Its activity against Candida albicans was weak.
Compounds 3a,b exhibited good growth inhibitory ac-
tivity against different fungal strains with MIC values
of 8–16 μg/mL. The 7-chloro-3-imidazolyl derivative
3c also showed good antifungal activity against Candida
albicans, Saccharomyces cerevisiae and Microsporum
gypseum (MIC=16 μg/mL), but its activity against A. niger
was moderate. The MIC values of fluconazole against
test strains were 8–32 μg/mL. Thus, the antifungal ac-
tivity of title compounds was comparable to that of
standard drug fluconazole. By comparing the MIC values
of hydrazone derivative 3b and its ketone counterpart
2b, it is revealed that the introduction of phenylhydra-
zone on chroman ring improves the antifungal activity
against all strains.
Previously, we have described azolylchromanone
oxime ethers as conformationally restricted analogs of
oxiconazole (Figure 1). Many of these derivatives exhibit
high activity against different fungal strains [6-8]. In this
work, we replaced O-benzyloxime ether fragment in azo-
lylchromanone derivatives by phenylhydrazone moiety.
The comparison of MIC values of triazole derivative 3a
with its O-benzyloxime ether counterpart demonstrates
that replacement of O-benzyloximino moiety withTable 1 In vitro antifungal activity of compounds 3a-c in
comparison with 2b and fluconazole
Compound Tested fungi (MICs in μg /mL)
C. albicans S. cerevisiae A. niger M. gypseum
2b 64 >64 >64 >64
3a 16 16 16 8
3b 8 16 16 16
3c 16 16 64 16
Fluconazole 8 32 32 32
Figure 4 Compound 2b (ball and stick) in the active site of
Mycobacterium P450 DM. For clarity, only the amino acids with
10 Ǻ distant from the compound 2b are shown.
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the cases of 3b and 3c, their O-benzyloximino analogs
have a better profile of antifungal activity.
Docking study
Azole antifungals such as fluconazole inhibit fungal
cytochrome P-450 dependent 14α-demethylase [4]. With
the aim of rationalizing the antifungal activity data
obtained, docking study was performed for the selected
derivatives 2b and 3a in order to investigate the possible
interactions with cytochrome P450 14α-sterol demethy-
lase from Mycobacterium tuberculosis (Mycobacterium
P450 DM). Because no experimental data are available
for the target enzyme Candida P450 DM in the Protein
Data Bank, the crystallographic structure of the complex
between Cytochrome P450 14α-sterol demethylase from
Mycobacterium tuberculosis (Mycobacterium P450 DM)
and fluconazole (ID 1EA1) was used for the docking
study [18].
Figure 3 shows the docked reference compound fluco-
nazole in the active site of the same enzyme for valid-
ation of our docking protocol and confirmation of the
biological data. Figures 4 and 5 show complex between
the enzyme's active site and compounds 2b and 3a, re-
spectively. The aromatic part of chroman ring of the
both compounds is situated in a lipophilic region and
interacts with Phe255, Met99, Phe83 and Met79. Oxygen
atom (sp3 hybridized) of the chroman ring is oriented
towards the polar region of the enzyme constituted by
Arg96 and Arg95. The phenyl attached to the hydrazone
moiety is inserted into a hydrophobic pocket above the
heme ring formed by ceiling residues Met79, Phe78,
Phe255, Val434, Leu321 and Tyr76. The azole ring of
both compounds 2b and 3a are positioned above theFigure 3 Computed binding geometry of the reference
compound fluconazole (ball and stick) in the active site of
Mycobacterium P450DM.porphyrine plan, with a ring nitrogen atom coordinated
to the heme iron. The distance between nitrogen atom
of compounds 2b and 3a and the heme iron is 2.6 Å
and 2.8 Å, respectively.
It has been previously reported that hydrophobic inter-
actions with Val434 is responsible for the potent inhibi-
tory activity of antifungals against Aspergillus niger
whereas hydrophobic interactions with Leu321, Ile323,
Leu324 may be responsible for an enhanced inhibitory
activity against Candida albicans and other Candida
spp. [18]. As shown in Figures 4 and 5, these interac-
tions only can be seen with compound 3a prototype
bearing lipophilic phenylhydrazone side chain and not
with compound 2b; explaining the major potency differ-
ences observed in obtained results between 2b and com-
pounds 3a-c.Figure 5 Compound 3a (ball and stick) in the active site of
Mycobacterium P450 DM. For clarity, only the amino acids with
10 Ǻ distant from the compound 3a are shown.
Table 2 Toxicity risks and physicochemical properties of compounds 3a-c in comparison with fluconazole, predicted by
OSIRIS Property Explorer
Compound Toxicity risks Physicochemical properties
Mutagenic Tumorigenic Irritant Reproductive effect CLogP Slobility MW Drug likeness Drug-score
3a (±) (+) (−) (±) 4.18 −3.07 305 1.33 0.26
3b (±) (+) (−) (−) 4.46 −2.78 318 2.81 0.34
3c (±) (+) (−) (±) 4.79 −3.14 338 0.17 0.2
Flu (−) (−) (−) (±) −0.21 −2.17 306 −1.13 0.46
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Currently, several approaches have been developed to
assess drug-likeness of bioactive compounds based on
topological descriptors, fingerprints of molecular struc-
ture or other properties such as molecular weight, water
solubility and cLogP [19]. In this work, open-source pro-
gram OSIRIS Property Explorer [14] was used to predict
the fragment-based drug-likeness of title compounds
and comparing them with fluconazole. OSIRIS program
involves the database of traded drugs and commercially
available compounds (Fluka) assumable as non drug-like
dataset to assess the occurrence frequency of each frag-
ment in the individual structure. The program estimated
the risks of side effects, such as mutagenic, tumorigenic,
irritant and reproductive effects, as well as drug-relevant
properties including cLogP, LogS (solubility), MW and
drug-likeness. Moreover, the overall drug-score was esti-
mated by combining outcome of cLogP, LogS, MW, tox-
icity risks and drug-likeness. Drug-score is a measure of
compound's potential to meet the criteria of a possible
drug candidate [14].
The in silico drug-relevant properties obtained by OS-
IRIS Property Explorer are given in Table 2. Interest-
ingly, the potential drug-likeness values of compounds
3a-c were significantly higher than that of fluconazole,
which showed a negative value of −1.13. As shown in
Table 2, compounds 3a-c had high in silico tumorigenic
and medium mutagenic toxicity risks due to the phenyl-
hydrazone moiety. However, the in silico prediction by
OSIRIS Property Explorer showed that the introduction
of chlorine on phenylhydrazone can reduce the risk of
tumorigenic and mutagenic toxicities. Generally, the
drug-score values of compounds 3a-c (0.2-0.34) were
less than that of fluconazole (0.46). Among the final
compounds, 2-methyl-3-imidazolyl derivative 3b showed
the highest values of drug-likeness and drug-score.
Conclusion
In conclusion, a series of 3-azolyl-4-chromanone phenyl-
hydrazones were synthesized via ring closure of 2-azolyl-
2'-hydroxyacetophenones and subsequent reaction with
phenylhydrazine. These compounds considered as ana-
logs of 3-azolyl-4-chromanone oxime ethers basically
designed as antifungal agents. The in vitro antifungalactivity of compounds based on MIC values revealed
that all compounds showed good antifungal activity against
Candida albicans, Saccharomyces cerevisiae and Micro-
sporum gypseum at concentrations less than 16 μg/mL.
The antifungal activity of title compounds was com-
parable to that of standard drug fluconazole. The bio-
logical data and docking study demonstrated that the
introduction of phenylhydrazone moiety on chroman
ring improves the antifungal activity. The 2-methyl-3-
imidazolyl derivative 3b which showed the highest
drug-likeness and drug-score values serves as a lead
for future development of antifungal agents.
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